Contrave: Phase III ongoing

Orexigen said it is enrolling patients faster than originally projected in the long-term, double-blind, placebo-controlled, U.S. Phase III (Light Study) trial, which is assessing the cardiovascular health outcomes of Contrave in up to 10,000 patients. Orexigen said it now expects to complete enrollment of the number of patients required for an interim analysis in 1Q13. The company said with the revised enrollment projections, it expects the trial to reach 87 MACE events in 2H13, at which...